MedTrace Logo

Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

NCT00163540 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-05-21

No results posted yet for this study

Summary

The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225. In Study 225, two vaccinations were given using a rapid immunization schedule 12 ± 2 days apart.

Conditions

  • Encephalitis, Tick-borne

Interventions

BIOLOGICAL

Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

Sponsors & Collaborators

Principal Investigators

  • Baxter BioScience Investigator, MD · Baxter BioScience

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Completion
2005-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00163540 on ClinicalTrials.gov